![Chao Hong Hu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Chao Hong Hu
Directeur/Membre du Conseil chez
HUTCHMED (CHINA) LIMITED
Fortune : 66 M $ au 31/05/2026
Profil
Chao Hong Hu was the founder of Shanghai Miracogen, Inc., founded in 2014, serving as Chairman & General Manager from 2014 to 2024.
Current jobs include Independent Non-Executive Director at BioDlink International Co., Ltd. since 2026 and Independent Non-Executive Director at HUTCHMED (China) Ltd. since 2024.
Former jobs include Co-Chief Executive Officer & Executive Director at Lepu Biopharma Co., Ltd. from 2020 to 2024, Director-Molecular Biology & Clinical Immunology at ID Biomedical Corp., Director-Bioassay Development & Process Analytics at Seagen, Inc. from 2007 to 2013, and Head-Molecular Biology & Clinical Immunology at GSK Plc from 2006 to 2007.
Education includes an undergraduate degree from Wuhan University in 1986 and a doctorate from the Chinese Academy of Sciences.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 11/07/2025 | 121 180 106 ( 6,72 % ) | 66 M $ | 31/05/2026 |
Postes actifs de Chao Hong Hu
| Sociétés | Poste | Début |
|---|---|---|
| HUTCHMED (CHINA) LIMITED | Directeur/Membre du Conseil | 21/11/2024 |
| BIODLINK INTERNATIONAL COMPANY LIMITED | Directeur/Membre du Conseil | 29/04/2026 |
Anciens postes connus de Chao Hong Hu
| Sociétés | Poste | Fin |
|---|---|---|
| LEPU BIOPHARMA CO., LTD. | Directeur Général | 31/01/2024 |
Shanghai Miracogen, Inc.
 Shanghai Miracogen, Inc. BiotechnologyHealth Technology Engages in development, clinical research and industrialization of cancer targeted therapy drugs | Directeur Général | 01/01/2024 |
| SEAGEN INC. | Corporate Officer/Principal | 01/10/2013 |
| GSK PLC | Corporate Officer/Principal | 01/05/2007 |
ID Biomedical Corp.
 ID Biomedical Corp. Medical SpecialtiesHealth Technology Develops gene-based disease testing and subunit vaccines | Corporate Officer/Principal | 01/01/2005 |
Formation de Chao Hong Hu
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
71
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
ID Biomedical Corp.
ID Biomedical Corp. Medical SpecialtiesHealth Technology Develops gene-based disease testing and subunit vaccines | Health Technology |
Seagen, Inc.
 Seagen, Inc. Pharmaceuticals: MajorHealth Technology Develops monoclonal antibody-based therapeutic products for treatment of cancer and immunologic diseases | Health Technology |
HUTCHMED (China) Ltd.
 HUTCHMED (China) Ltd. Pharmaceuticals: MajorHealth Technology Engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products | Health Technology |
GSK Plc
 GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
Wuhan University
 Wuhan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Chinese Academy of Sciences
 Chinese Academy of Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TOT BIOPHARM International Co. Ltd.
 TOT BIOPHARM International Co. Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets anti-tumor drugs | Health Technology |
Lepu Biopharma Co., Ltd.
 Lepu Biopharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Shanghai Miracogen, Inc.
Shanghai Miracogen, Inc. BiotechnologyHealth Technology Engages in development, clinical research and industrialization of cancer targeted therapy drugs | Health Technology |
Choisissez Zonebourse 
